Table of Contents

Research Articles: Therapeutics, Targets, and Development

• Research Articles: Therapeutics, Targets, and Development

  Characterization of novel inhibitors of histone acetyltransferases

  Elena D. Eliseeva, Vassil Valkov, Manfred Jung and Mira O. Jung

  Mol Cancer Ther September 1 2007 6 (9) 2391-2398; DOI:10.1158/1535-7163.MCT-07-0159

  
  
• Research Articles: Therapeutics, Targets, and Development

  Improved low molecular weight Myc-Max inhibitors

  Huabo Wang, Dalia I. Hammoudeh, Ariele Viacava Follis, Brian E. Reese, John S. Lazo, Steven J. Metallo and Edward V. Prochownik

  Mol Cancer Ther September 1 2007 6 (9) 2399-2408; DOI:10.1158/1535-7163.MCT-07-0005

  
  
• Research Articles: Therapeutics, Targets, and Development

  The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo

  Malin Wickström, John Inge Johnsen, Frida Ponthan, Lova Segerström, Baldur Sveinbjörnsson, Magnus Lindskog, Henrik Lövborg, Kristina Viktorsson, Rolf Lewensohn, Per Kogner, Rolf Larsson and Joachim Gullbo

  Mol Cancer Ther September 1 2007 6 (9) 2409-2417; DOI:10.1158/1535-7163.MCT-07-0156

  
  
• Research Articles: Therapeutics, Targets, and Development

  Structural modulation of reactivity/activity in design of improved benzothiophene selective estrogen receptor modulators: induction of chemopreventive mechanisms

  Bolan Yu, Birgit M. Dietz, Tareisha Dunlap, Irida Kastrati, Daniel D. Lantvit, Cassia R. Overk, Ping Yao, Zhihui Qin, Judy L. Bolton and Gregory R.J. Thatcher

  Mol Cancer Ther September 1 2007 6 (9) 2418-2428; DOI:10.1158/1535-7163.MCT-07-0268

  
  
• Research Articles: Therapeutics, Targets, and Development

  Gambogic acid inhibits the catalytic activity of human topoisomerase IIα by binding to its ATPase domain

  Yuxin Qin, Linghua Meng, Chaoxin Hu, Wenhu Duan, Zhili Zuo, Liping Lin, Xiongwen Zhang and Jian Ding

  Mol Cancer Ther September 1 2007 6 (9) 2429-2440; DOI:10.1158/1535-7163.MCT-07-0147

  
  
• Research Articles: Therapeutics, Targets, and Development

  Synthesis and biological activity of stable branched neurotensin peptides for tumor targeting

  Chiara Falciani, Monica Fabbrini, Alessandro Pini, Luisa Lozzi, Barbara Lelli, Silvia Pileri, Jlenia Brunetti, Stefano Bindi, Silvia Scali and Luisa Bracci

  Mol Cancer Ther September 1 2007 6 (9) 2441-2448; DOI:10.1158/1535-7163.MCT-07-0164

  
  
• Research Articles: Therapeutics, Targets, and Development

  The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion

  Anita B. Hjelmeland, Kathryn P. Lattimore, Brian E. Fee, Qing Shi, Sarah Wickman, Stephen T. Keir, Mark D. Hjelmeland, David Batt, Darell D. Bigner, Henry S. Friedman and Jeremy N. Rich

  Mol Cancer Ther September 1 2007 6 (9) 2449-2457; DOI:10.1158/1535-7163.MCT-07-0155

  
  
• Research Articles: Therapeutics, Targets, and Development

  The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo

  Lesley-Ann Martin, Julia E. Head, Sunil Pancholi, Janine Salter, Emma Quinn, Simone Detre, Stan Kaye, Angela Howes, Mitch Dowsett and Stephen R.D. Johnston

  Mol Cancer Ther September 1 2007 6 (9) 2458-2467; DOI:10.1158/1535-7163.MCT-06-0452

  
  
• Research Articles: Therapeutics, Targets, and Development

  AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma

  Hung Huynh, Pierce K.H. Chow and Khee-Chee Soo

  Mol Cancer Ther September 1 2007 6 (9) 2468-2476; DOI:10.1158/1535-7163.MCT-07-0162

  
  
• Research Articles: Therapeutics, Targets, and Development

  The radiosensitization effect of parthenolide in prostate cancer cells is mediated by nuclear factor-κB inhibition and enhanced by the presence of PTEN

  Yulan Sun, Daret K. St. Clair, Fang Fang, Graham W. Warren, Vivek M. Rangnekar, Peter A. Crooks and William H. St. Clair

  Mol Cancer Ther September 1 2007 6 (9) 2477-2486; DOI:10.1158/1535-7163.MCT-07-0186

  
  
• Research Articles: Therapeutics, Targets, and Development

  Thiothymidine plus low-dose UVA kills hyperproliferative human skin cells independently of their human papilloma virus status

  Olivier Reelfs, Yao-Zhong Xu, Andrew Massey, Peter Karran and Alan Storey

  Mol Cancer Ther September 1 2007 6 (9) 2487-2495; DOI:10.1158/1535-7163.MCT-07-0166

  
  
• Research Articles: Therapeutics, Targets, and Development

  Hypoxia modulation and radiosensitization by the novel dual EGFR and VEGFR inhibitor AEE788 in spontaneous and related allograft tumor models

  Christoph Oehler-Jänne, Wolfram Jochum, Oliver Riesterer, Angela Broggini-Tenzer, Giorgio Caravatti, Van Vuong and Martin Pruschy

  Mol Cancer Ther September 1 2007 6 (9) 2496-2504; DOI:10.1158/1535-7163.MCT-07-0253

  
  
• Research Articles: Therapeutics, Targets, and Development

  The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures

  Amy L. Howes, Gary G. Chiang, Elizabeth S. Lang, Caroline B. Ho, Garth Powis, Kristiina Vuori and Robert T. Abraham

  Mol Cancer Ther September 1 2007 6 (9) 2505-2514; DOI:10.1158/1535-7163.MCT-06-0698

  
  
• Research Articles: Therapeutics, Targets, and Development

  Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor–dependent human lung cancer cells

  Arthur Edwards, Jiannong Li, Peter Atadja, Kapil Bhalla and Eric B. Haura

  Mol Cancer Ther September 1 2007 6 (9) 2515-2524; DOI:10.1158/1535-7163.MCT-06-0761

  
  
• Research Articles: Therapeutics, Targets, and Development

  Histone deacetylase inhibitors selectively suppress expression of HDAC7

  Milos Dokmanovic, Gisela Perez, Weisheng Xu, Lang Ngo, Cathy Clarke, Raphael B. Parmigiani and Paul A. Marks

  Mol Cancer Ther September 1 2007 6 (9) 2525-2534; DOI:10.1158/1535-7163.MCT-07-0251

  
  
• Research Articles: Therapeutics, Targets, and Development

  Reactive oxygen species mediated apoptosis of esophageal cancer cells induced by marine triprenyl toluquinones and toluhydroquinones

  Catherine E. Whibley, Kerry L. McPhail, Robert A. Keyzers, Michelle F. Maritz, Virna D. Leaner, Michael J. Birrer, Michael T. Davies-Coleman and Denver T. Hendricks

  Mol Cancer Ther September 1 2007 6 (9) 2535-2543; DOI:10.1158/1535-7163.MCT-06-0760

  
  
• Research Articles: Therapeutics, Targets, and Development

  Kaempferol induces apoptosis in glioblastoma cells through oxidative stress

  Vivek Sharma, Christy Joseph, Soumya Ghosh, Anindita Agarwal, Manoj Kumar Mishra and Ellora Sen

  Mol Cancer Ther September 1 2007 6 (9) 2544-2553; DOI:10.1158/1535-7163.MCT-06-0788

  
  
• Research Articles: Therapeutics, Targets, and Development

  Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma

  Won Kim, Jung-Hwan Yoon, Jae-Min Jeong, Gi-Jeong Cheon, Tae-Sup Lee, Jong-In Yang, Su-Cheol Park and Hyo-Suk Lee

  Mol Cancer Ther September 1 2007 6 (9) 2554-2562; DOI:10.1158/1535-7163.MCT-07-0115

  
  
• Research Articles: Therapeutics, Targets, and Development

  Involvement of specific matrix metalloproteinases during tumor necrosis factor/IFNγ–based cancer therapy in mice

  Maarten Van Roy, Philippe Van Lint, Ineke Van Laere, Ben Wielockx, Carole Wilson, Carlos López-Otin, Stephen Shapiro and Claude Libert

  Mol Cancer Ther September 1 2007 6 (9) 2563-2571; DOI:10.1158/1535-7163.MCT-07-0016

  
  
• Research Articles: Therapeutics, Targets, and Development

  Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter

  Jae Yeon Chun, Yan Hu, Elaine Pinder, Jianguo Wu, Fengzhi Li and Allen C. Gao

  Mol Cancer Ther September 1 2007 6 (9) 2572-2580; DOI:10.1158/1535-7163.MCT-07-0172

  
  
• Research Articles: Therapeutics, Targets, and Development

  Enterolactone induces apoptosis in human prostate carcinoma LNCaP cells via a mitochondrial-mediated, caspase-dependent pathway

  Li-Hua Chen, Jing Fang, Huaixing Li, Wendy Demark-Wahnefried and Xu Lin

  Mol Cancer Ther September 1 2007 6 (9) 2581-2590; DOI:10.1158/1535-7163.MCT-07-0220

  
  
• Research Articles: Therapeutics, Targets, and Development

  Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts

  Faiy H. Psahoulia, Konstantinos G. Drosopoulos, Lenka Doubravska, Ladislav Andera and Alexander Pintzas

  Mol Cancer Ther September 1 2007 6 (9) 2591-2599; DOI:10.1158/1535-7163.MCT-07-0001

  
  
• Research Articles: Therapeutics, Targets, and Development

  A platelet biomarker for assessing phosphoinositide 3-kinase inhibition during cancer chemotherapy

  Rita K. Bowers, Philip Marder, Lisa J. Green, Candice L. Horn, Andrew L. Faber and James E. Thomas

  Mol Cancer Ther September 1 2007 6 (9) 2600-2607; DOI:10.1158/1535-7163.MCT-06-0746